These foods are the heaviest hitters. While GLP-1 drugs have transformed how many people think about weight loss, the ...

New research being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (May 12–15), reveals ...

A newly studied hormone is revealing an unexpected connection between metabolism and the brain. A hormone that can reverse ...

Novo Nordisk A/S (NYSE:NVO) is one of the undervalued large cap stocks to buy. On April 7, Novo Nordisk A/S (NYSE:NVO) said ...

Study of almost 28,000 people also identifies genetic variants that raise the risk of gastrointestinal side effects from ...

The global rise in the prevalence of obesity highlights the need for accessible and effective solutions for obesity ...

With a second oral GLP-1 for obesity now approved in the U.S., analysts have set to work parsing the blockbuster potential of ...

Revised diagnostic framework may limit access to early treatment, widen healthcare dispari ...

Novo Nordisk’s oral Wegovy has a few months’ head start on Eli Lilly’s newly approved pill. While the Indianapolis pharma has ...

A major update to how obesity is defined could push U.S. obesity rates to nearly 70%, according to a large new study. The change comes from adding waist and body fat measurements to BMI, capturing ...

Pennsylvania’s Medicaid spending for GLP-1s like Ozempic, Wegovy, and Zepbound exploded to an estimated $1.3 billion last year — from $233 million in 2022, the year before Medicaid started covering ...